NUWE
Nuwellis, Inc. (NASDAQ)
Healthcare — Medical Devices
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure, as well as Aquadex SmartFlow system for temporary use in adult and pediatric patients. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
None
$3.14
+$0.09 (+2.95%)
Sign in to add NUWE to a watchlist or set price alerts.
Price History
52-Week Range
Fundamentals
| Market Cap | $1.14M |
| P/E Ratio (TTM) | - |
| Forward P/E | -1.21 |
| EPS (TTM) | $-941.19 |
| Dividend Yield | - |
| Profit Margin | -217.22% |
| Revenue Growth | 26.20% |
| ROE | -609.44% |
| Debt/Equity | 9.93 |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 9.3 |
| Beta | 0.17 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $908.25 |
| 52-Week Low | $2.80 |
| 50-Day Avg | $23.54 |
| 200-Day Avg | $67.50 |
| Avg Volume | 79.4K |
| Volume | 242.7K |
Performance Analysis
NEUTRALNUWE presents a mixed picture with both positive and negative indicators.
+
Trading near its 52-week low ($2.80), which could present a value opportunity.
+
RSI at 9.3 signals oversold conditions — a bounce may be ahead.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
+
Strong revenue growth of 26.2% year-over-year.
-
Operating at a loss with -217.2% margin.
~
Wall Street consensus is "none".
Recent News
Loading news...
Last updated: Jul 02, 2026 13:23 UTC
Back to Screener Export Report